Randomized trial · people

Exenatide: no significant drop in heart events vs placebo in EXSCEL

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In a large trial, once-weekly exenatide did not raise major heart events in type 2 diabetes, but it also did not significantly lower them compared with placebo.

Kind
Randomized trial
Studied in
People
Number studied
14752
Published
2017
Journal
N Engl J Med

What they tested

The team tested whether adding once-weekly exenatide to usual care was safe for the heart in type 2 diabetes, and whether it cut major heart events.

How the study was done

A randomized, placebo-controlled trial in 14,752 people with type 2 diabetes, 73.1% of whom already had cardiovascular disease. They got 2 mg extended-release exenatide or a matching placebo (dummy) shot once a week and were followed for a median of 3.2 years.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking exenatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

The main outcome was a first heart attack, stroke or death from heart causes. It happened in 839 of 7356 people (11.4%) on exenatide and 905 of 7396 people (12.2%) on placebo, a hazard ratio (relative risk over time) of 0.91 (95% CI 0.83 to 1.00). Exenatide met the bar for being no worse than placebo on safety (P<0.001), but not for being better (P=0.06). Heart deaths, heart attacks, strokes, heart failure hospital stays, pancreatitis, pancreatic cancer, medullary thyroid cancer and serious side effects did not differ significantly between groups.

What it doesn’t show

The trial tested only the 2 mg once-weekly form in people with type 2 diabetes, so it does not speak to other doses or to people without diabetes. It was funded by Amylin Pharmaceuticals.

The paper

Holman et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017.

The compound

More studies on Exenatide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking exenatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo